Recently, the Journal of Functional Food published online a collaboration between Professor Liu Shanshan and Professor Zhang Shuzhen from the Key Laboratory of Soybean Biology of the Ministry of Education of Northeast Agricultural University entitled 'Breeding of 'DND358': A new soybean cultivar for processing soy protein isolate with a hypocholesterolmic Effect similar to that of fenofibrate's research paper.
In recent years, cardiovascular and cerebrovascular diseases have shown an epidemic trend in the world, and the results of epidemiological investigations show that in developed countries, cardiovascular and cerebrovascular diseases are the "number one killer" causing death. Hypercholesterolemia is one of the high risk factors for various cardiovascular diseases. In the course of treatment of hypercholesterolemia, drug therapy is generally accompanied by various side effects. At present, the world's health organizations are vigorously advocating the prevention and treatment of cardiovascular and cerebrovascular diseases by adjusting the dietary structure, and soy protein has become the preferred raw material for cholesterol-lowering special health food because of its unique high-efficiency cholesterol-lowering function. The U.S. Food and Drug Administration, the Canadian Food Inspectorate, and Japan's Ministry of Health and Welfare have all approved soy protein as a special health-use food for lowering blood cholesterol levels. However, so far, there are no reports at home and abroad on the special soybean varieties of 'cholesterol-lowering special health uses'.
After 16 years of efforts, the research group of Professor Liu Shanshan/Zhang Shuzhen has created the world's first new soybean variety with Chinese soybean genetic background, 'cholesterol-lowering special health purposes': 'Dongnong Bean 358'. Based on the normal subunits 'Dongnong 47', 'Suinong 10' and the rare breeding material 'HS99B' with multiple subunit deletions, the research group adopted the 'Dongnong 47/HS99B//Suinong 10' binding method, and successfully introduced soybean 7S globulin α subunit, 11S globulin G1 (A1aB2), G2 (A2B1a) and G4 (A5A4B3) subunit recessive deletion genes into the genetic background of Soybean in China, and bred simultaneously lost α/G1/G2/ G4 tetraunit, genotype 'cgy-2/gy1/gy2/gy4' mutant varieties of 'four deficiencies'. The absence of multiple subunits led to a significant increase in the arginine content of 'Dongnong Bean 358', and α' subunits were greatly enriched.
The results of animal experiments showed that the high-purity, cholesterol-lowering protein powder (DND358-SPI) produced from 'Dongnong Bean 358' could significantly reduce fatty liver symptoms, liver fat accumulation and fat cell hypertrophy in high-cholesterol model mice; significantly reduce liver total cholesterol and triglyceride levels; continuous feeding of DND358-SPI for one month, high-cholesterol model rat liver and fat tissue morphology close to normal diet healthy mice, especially in decreased' On the atherosclerotic index, a key indicator of cardiovascular and cerebrovascular diseases, DND358-SPI has a more significant therapeutic effect than the cholesterol-lowering drug "fenofibrate". The cholesterol-lowering special soybean protein powder produced by 'Dongnong Bean 358' can be completely realized by replacing "medicinal therapy" with "dietary therapy", and avoids all the adverse side effects produced by "fenofibrate", which will make a great contribution to the improvement and improvement of the health level of high cholesterol patients. Because the effective reduction of blood cholesterol content is the fundamental measure to treat and prevent all cardiovascular and cerebrovascular diseases, therefore, patients with cerebral hemorrhage, hypertension, heart disease and all cardiovascular and cerebrovascular diseases can safely use DND358-SPI, and because soy protein avoids the side effects of drugs, not only can treat cardiovascular diseases, but also is generally suitable for consumers with health care and health needs. Therefore, its consumer market is far more than the 330 million patients with cardiovascular and cerebrovascular diseases in the mainland, but also includes various soybean protein isolate food factories. Cholesterol-lowering special soybean 'Dongnong Bean 358' has great development potential in the functional food market and has a promising future. This study provides a new germplasm of high-quality and special soybeans for building a whole industry chain system of soybean functional high-quality foods in mainland China, helping the rejuvenation of the soybean industry in mainland China, and improving people's health.
As mankind enters the 'era of preventive medicine', functional food has become the most promising and challenging industry full of development opportunities in the food industry in the new century. Products that reduce the risk of disease are one of the main channels for the development of functional foods in the future, and the research group will use 'Dongnong Bean 358' as raw material to build DND358-SPI into the most convenient way of dietary therapy for cardiovascular and cerebrovascular diseases, and create a boutique of soybean functional foods in mainland China.
The above research was completed by the Key Laboratory of Soybean Biology of the Ministry of Education of Northeast Agricultural University, with Associate Professor Song Bo as the first author, Professor Liu Shanshan, Professor Zhang Shuzhen and Professor Xu Pengfei as co-corresponding authors. This work has been funded by the National Key Research and Development Project and the National Natural Science Foundation of China. ('Dongnong Bean 358', approved and promoted by the Heilongjiang Provincial Crop Variety Approval Committee in June 2021, the approval number is: Black Trial Bean 20210046.) ）
Original link:
https://doi.org/10.1016/j.jff.2022.104979
The forefront of plant science, focusing on the frontier progress of plant science, information, the release of recruitment information and method software sharing. For submission and recruitment, please reply to the "submission" in the background, all of which are free; for business cooperation, please contact WeChat ID: zwkxqy;